买欧洲杯预选赛盘口

<bdo id="r4zx5"><object id="r4zx5"></object></bdo>

<listing id="r4zx5"></listing>

<del id="r4zx5"><dl id="r4zx5"><big id="r4zx5"></big></dl></del><del id="r4zx5"><dl id="r4zx5"><small id="r4zx5"></small></dl></del>

  1. <u id="r4zx5"><pre id="r4zx5"></pre></u>
    1. <dfn id="r4zx5"></dfn>

      <del id="r4zx5"><source id="r4zx5"><big id="r4zx5"></big></source></del>

      <ins id="r4zx5"></ins>

      <tt id="r4zx5"><source id="r4zx5"><big id="r4zx5"></big></source></tt>

      <listing id="r4zx5"><input id="r4zx5"></input></listing>
      <u id="r4zx5"><pre id="r4zx5"></pre></u>
      Home» Events

      Notice of " Ryanodine receptor: structure based insights into human genetic diseases"

      Sourse:   Date:2019-12-11

      Speaker:Andrew Robert. Marks(Columbia University,USA)

      Time:16:00 pm, December 12, 2019

      Venue:A213 of Science building 

      Introduction of Speaker: 

      Prof. Marks is a member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He isChair and Professor of the Physiology and Cellular Biophysics Department andProfessor of the Pharmacology at Columbia University. Prof. Marksused to be Editor-in-Chief of the Journal of Clinical Investigation, and he enjoys a high academic reputation in the fields of pharmacology and cell biology.His research focuses on the calcium channel function, and the mechanism and therapeutic drugs of Ryanodine receptor in cardiovascular system, lymphocyte function, cognitive dysfunction and muscular atrophy. He identified the inhibitory mechanism of rapamycin on vascular smooth muscle proliferation and migration, leading to the development of the first drug-eluting stent (coated with rapamycin) for treatment of coronary artery disease. Prof. Marks discovered a new class of small molecules (Rycals) thathave shown promising results in pilot clinical trials for thetreatment of heart failure and Alzheimer’sdisease. Prof. Marks is Chair of the Scientific Advisory Board (SAB) of the RYR-1 Foundation and of ARMGO Pharma, Inc. A biotech company focused on developing therapeutics targeting leaky RyR channels.In the past years, Prof. Marks published over 120 papers in international famous journals such as Science, Cell, PNAS, Journal of Clinical Investigation and Circulation.

      Shaanxi Key Laboratory of Natural Products & Chemical Biology

      College of Chemistry & Pharmacy

      Dec.9,2019


      <bdo id="r4zx5"><object id="r4zx5"></object></bdo>

      <listing id="r4zx5"></listing>

      <del id="r4zx5"><dl id="r4zx5"><big id="r4zx5"></big></dl></del><del id="r4zx5"><dl id="r4zx5"><small id="r4zx5"></small></dl></del>

      1. <u id="r4zx5"><pre id="r4zx5"></pre></u>
        1. <dfn id="r4zx5"></dfn>

          <del id="r4zx5"><source id="r4zx5"><big id="r4zx5"></big></source></del>

          <ins id="r4zx5"></ins>

          <tt id="r4zx5"><source id="r4zx5"><big id="r4zx5"></big></source></tt>

          <listing id="r4zx5"><input id="r4zx5"></input></listing>
          <u id="r4zx5"><pre id="r4zx5"></pre></u>

          天奇彩票平台-首页

          幸福彩票网址

          黄金娱乐场

          wwww88优德com

          福建福彩网

          大奖娱乐www.ptpt9.com

          体育比分网

          在线娱乐赌博平台

          球探比分即时足球比分